BR0117171A - Composição farmacêutica para liberação controlada de um antibiótico do tipo beta-lactama - Google Patents

Composição farmacêutica para liberação controlada de um antibiótico do tipo beta-lactama

Info

Publication number
BR0117171A
BR0117171A BR0117171-2A BR0117171A BR0117171A BR 0117171 A BR0117171 A BR 0117171A BR 0117171 A BR0117171 A BR 0117171A BR 0117171 A BR0117171 A BR 0117171A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
water
controlled release
active ingredient
beta
Prior art date
Application number
BR0117171-2A
Other languages
English (en)
Inventor
Himadri Sen
Rajesh Suresh Kshirsagar
Shailesh Suresh Bhamare
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR0117171A publication Critical patent/BR0117171A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA LIBERAçãO CONTROLADA DE UM ANTIBIóTICO DO TIPO BETA-LACTAMA". Que e uma composição farmacêutica estável e melhorada para liberação controlada de um ingrediente ativo compreende um antibiótico do tipo betalactama tal como cefalexina, cefaclor ou seus hidratos, sais ou ésteres farmaceuticamente aceitáveis como ingrediente ativo, um sal de cálcio e uma mistura de polímeros hidrófilos selecionados do grupo que consiste de pelo menos um alginato de sódio e uma goma xantana e com ou sem hidroxipropil metilcelulose, a referida composição opcionalmente contendo probenecida. A composição também pode conter um ou mais de um diluente solúvel em água e/ou dispersível em água, onde as quantidades dos polímeros hidrófilos e dos diluentes solúveis em água e/ou dispersíveis em água são tais que o ingrediente ativo terapeuticamente eficaz e liberado a uma taxa adequada para administração da composição farmacêutica uma ou duas vezes ao
BR0117171-2A 2001-11-19 2001-11-19 Composição farmacêutica para liberação controlada de um antibiótico do tipo beta-lactama BR0117171A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000204 WO2003043607A1 (en) 2001-11-19 2001-11-19 A pharmaceutical composition for controlled release of a beta-lactam antibiotic

Publications (1)

Publication Number Publication Date
BR0117171A true BR0117171A (pt) 2004-10-26

Family

ID=11076411

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0117171-2A BR0117171A (pt) 2001-11-19 2001-11-19 Composição farmacêutica para liberação controlada de um antibiótico do tipo beta-lactama

Country Status (11)

Country Link
US (1) US8192755B2 (pt)
EP (1) EP1461017B1 (pt)
AT (1) ATE319434T1 (pt)
AU (1) AU2002224011B2 (pt)
BR (1) BR0117171A (pt)
CY (1) CY1105365T1 (pt)
DE (1) DE60117712T2 (pt)
DK (1) DK1461017T3 (pt)
ES (1) ES2259011T3 (pt)
PT (1) PT1461017E (pt)
WO (1) WO2003043607A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
EP1680089B1 (en) 2003-10-22 2013-09-11 Lidds AB Composition comprising biodegradable hydrating ceramics for controlled drug delivery
US7807715B2 (en) 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
US9050357B2 (en) * 2010-03-08 2015-06-09 Cp Kelco U.S., Inc. Compositions and methods for producing consumables for patients with dysphagia
RU2470671C1 (ru) * 2011-07-06 2012-12-27 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ обработки текстильных изделий для сердечно-сосудистой хирургии
CN107661507A (zh) * 2017-10-30 2018-02-06 四川飞扬动物药业有限公司 兽用肠溶长效复方阿莫西林粉及其制备方法
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
CA3129337A1 (en) * 2019-02-13 2020-08-20 Iterum Therapeutics International Limited Combinations of beta-lactam compounds and probenecid and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6055486B2 (ja) 1976-02-28 1985-12-05 富山化学工業株式会社 β−ラクタム環を有する化合物の直腸投与用組成物
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
CZ2001901A3 (cs) 1998-09-14 2001-08-15 Ranbaxy Laboratories Limited Farmaceutická kompozice představující systém řízeného dodávání léku pro orální podání, poskytující časovou a místní kontrolu
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
CA2473503C (en) 2002-01-14 2010-01-05 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation

Also Published As

Publication number Publication date
ES2259011T3 (es) 2006-09-16
EP1461017B1 (en) 2006-03-08
EP1461017A1 (en) 2004-09-29
PT1461017E (pt) 2006-07-31
DE60117712T2 (de) 2006-11-16
US20050031685A1 (en) 2005-02-10
WO2003043607A1 (en) 2003-05-30
ATE319434T1 (de) 2006-03-15
CY1105365T1 (el) 2010-03-03
AU2002224011B2 (en) 2008-05-01
DE60117712D1 (de) 2006-05-04
AU2002224011A1 (en) 2003-06-10
US8192755B2 (en) 2012-06-05
DK1461017T3 (da) 2006-06-19

Similar Documents

Publication Publication Date Title
HRP20060275A2 (en) 6-0-supstituted ketolides having antibacterial activity
JP2003321389A5 (pt)
AU4882597A (en) Pharmaceutical preparations for the controlled release of beta-lactam antibiotics
EP2295402A3 (en) Antibacterial agents
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
CA2292359A1 (en) Novel azalides and methods of making same
CA2359708A1 (en) Ketolide antibiotics
AU5669298A (en) Cyclosporin derivatives, their preparation and pharmaceutical compositions containing them
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
AU678344B2 (en) Lipophilic oligosaccharide antibiotic salt compositions
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
EA200400701A1 (ru) 13-членные азалиды и их применение в качестве антибиотических агентов
BR0117171A (pt) Composição farmacêutica para liberação controlada de um antibiótico do tipo beta-lactama
JP2000159790A5 (pt)
WO2004096822A3 (en) Pyridyl substituted ketolide antibiotics
MX2022016263A (es) Derivados de ciclobutil-urea.
JP2003171274A (ja) 薬剤耐性菌感染症治療のための医薬組成物および消毒剤
CA2483875A1 (en) 6,11 bicyclic erythromycin derivatives
HRP20090022T3 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
US20040229825A1 (en) Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant
DE69734678D1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
BR0013283A (pt) Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo
Hamilton-Miller Dual-action antibiotic hybrids
BR0011845A (pt) Complexo farmacêutico

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A 3A ANUIDADE DE ACORDO COM A TABELA VIGENTE,CUJA GUIA ( 220401090201 )

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]